Physician profile
Mark David Richardson
NPI 1669449443
$1,853.20
in general payments reported to CMS, 2019-2025
27 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $235 · 2021: $234 · 2022: $358 · 2023: $416 · 2024: $252 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $270.28 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $178.96 | 2019-2024 | Veozah |
| Novo Nordisk INC | $144.61 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $127.35 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $101.13 | 2019-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $93.69 | 2022-2025 | Airsupra, Nexium, Farxiga |
| Lilly USA, LLC | $64.71 | 2021-2024 | Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.48 | 2020-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $53.82 | 2022 | |
| Sumitomo Pharma America, INC. | $42.18 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $39.90 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $39.15 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.43 | 2020-2023 | Eliquis |
| Amgen INC. | $29.28 | 2022-2023 | Evenity, Prolia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $27.82 | 2021-2023 | Krystexxa |
| Boston Scientific Corporation | $24.41 | 2023 | |
| Jazz Pharmaceuticals INC. | $24.15 | 2022 | |
| Collegium Pharmaceutical, INC. | $23.30 | 2020-2021 | |
| Amarin Pharma, INC. | $19.28 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.17 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $18.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.83 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $17.19 | 2023 | Spravato |
| Corium, LLC | $15.70 | 2023 | Azstarys |
| Mylan Specialty L.P. | $13.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.